MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

Agmatine-based pain treatment avoids opioid addiction

University of Minnesota

The search for better analgesics has focused on non-addictive alternatives. Agmatine, the decarboxylated product of arginine, is a potential candidate for novel therapeutics.

Currently, over 100 million adults in the United States experience chronic pain, highlighting a significant clinical need. However, there are limited options for safe and efficacious treatments for patients experiencing chronic pain despite years of research on different therapeutics. Opioids are the gold standard treatment for chronic pain, but these medications have significant addiction and tolerance side effects associated with the exploding opioid abuse epidemic. Together there is need for new interventions with superior analgesic properties and limited undesirable side effects.

Agmatine has previously been shown to reduce chronic pain and block opioid tolerance and dependence. However, agmatine is a highly polar molecule and thus is not conducive to delivery across the blood brain barrier itself. Therefore, the current technology aims to deliver strategically substituted agmatine (SSA) molecules systemically that can cross the blood brain barrier more readily and allow for chronic pain reduction.

Based on compelling pre-clinical data, these SSAs could be used in cases of neuropathic pain, opioid addiction and opioid analgesic tolerance.

Features/Benefits

  • Non-addictive: Blocks opioid tolerance and dependence.
  • Reverses chronic pain: Decreases pain associated with inflammation and nerve injury.
  • Permeates the blood-brain barrier and readily achieves a potent analgesic effect.

Applications

  • Inflammatory pain
  • Neuropathic pain
  • Spinal cord injury

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights
  • Today's the day!
    491 days ago
  • Schedule is set for the 2021 MidWest Drug Development Conference. Register today! https://t.co/5SvzL4EhuV
    504 days ago
  • No surprise to see some incredible innovations out of @UWMadison that could change drug delivery approaches, cancer… https://t.co/h90yfHwC5k
    505 days ago

Follow us! @DrugMw